Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis.

about

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis.

Item

http://www.wikidata.org/entity/Q50212100

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis.

@en

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis.

@nl

type

Item

label

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis.

@en

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis.

@nl

prefLabel

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis.

@en

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis.

@nl

P1476

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis.

@en

P2093

Aoyuan Cui

http://www.w3.org/2001/XMLSchema#string

Yamei Han

http://www.w3.org/2001/XMLSchema#string

Yi Yang

http://www.w3.org/2001/XMLSchema#string

Yu Li

http://www.w3.org/2001/XMLSchema#string

Zhimin Hu

http://www.w3.org/2001/XMLSchema#string

P2860

AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity

Nonalcoholic fatty liver disease

Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.

Human fatty liver disease: old questions and new insights

Animal models of nonalcoholic fatty liver disease.

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier.

Hepatic ATF6 Increases Fatty Acid Oxidation to Attenuate Hepatic Steatosis in Mice Through Peroxisome Proliferator-Activated Receptor α.

P31

scholarly article

P356

10.3791/55178

http://www.w3.org/2001/XMLSchema#string

P433

121

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28362401

http://www.w3.org/2001/XMLSchema#string

P932

5408851

http://www.w3.org/2001/XMLSchema#string